# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059118
Filing Date
2024-05-14
Accepted
2024-05-14 08:30:37
Documents
76
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | cadl-20240331.htm iXBRL | 10-Q | 1940960
2 | EX-31.1 | cadl-ex31_1.htm | EX-31.1 | 15830
3 | EX-31.2 | cadl-ex31_2.htm | EX-31.2 | 15617
4 | EX-32.1 | cadl-ex32_1.htm | EX-32.1 | 8177
5 | EX-32.2 | cadl-ex32_2.htm | EX-32.2 | 8574
| Complete submission text file | 0000950170-24-059118.txt |  | 7707213

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | cadl-20240331.xsd | EX-101.SCH | 1418341
80 | EXTRACTED XBRL INSTANCE DOCUMENT | cadl-20240331_htm.xml | XML | 948688

Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 24941562
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)